Zollinger‑Ellison Disease (Gastrinoma) – A Complete Patient Guide

Overview

Zollinger‑Ellison disease (ZED) is a rare, usually malignant, tumor of the pancreas or duodenum that secretes excessive amounts of the hormone gastrin. The high gastrin levels cause the stomach to produce large volumes of acid, leading to severe peptic ulcer disease and a range of gastrointestinal symptoms.

• Classification: A type of functional neuroendocrine tumor (NET) called a gastrinoma.
• Incidence: Approximately 1–3 cases per million people per year in the United States.^[1]
• Prevalence: Roughly 0.1 % of all patients with peptic ulcer disease have ZED.^[2]
• Age & gender: Most commonly diagnosed between 40–60 years; slight male predominance (1.3 : 1).^[3]
• Associated syndromes: About 20–30 % occur as part of Multiple Endocrine Neoplasia type 1 (MEN‑1), a hereditary condition that also includes parathyroid and pituitary tumors.^[4]

Symptoms

Symptoms arise from hyperacidic gastric secretions and from the tumor itself. They may be intermittent early on and become constant as disease progresses.

Gastrointestinal symptoms

• Refractory peptic ulcers: Ulcers that fail to heal despite standard therapy; often located beyond the duodenum (jejunum, ileum).
• Abdominal pain: Burning or cramping pain, typically 2–3 hours after meals.
• Diarrhea: Frequent, watery stools caused by acid inactivating pancreatic enzymes.
• Steatorrhea (fatty stools): Malabsorption of fats leading to foul‑smelling, bulky stools.
• Nausea & vomiting: Can be triggered by the high‑acid environment.
• Weight loss: Due to malabsorption, pain‑related anorexia, and increased metabolic demand.

Systemic symptoms

• Gastro‑oesophageal reflux disease (GERD): Burning chest pain, sour taste.
• Gastrointestinal bleeding: Hematemesis or melena from ulcer erosion.
• Fatigue: Often secondary to anemia from chronic bleeding.
• Electrolyte disturbances: Low potassium and magnesium from chronic diarrhea.

Symptoms related to MEN‑1 (if present)

• Hyperparathyroidism (stones, bone pain, psychiatric symptoms)
• Pituitary adenoma (headaches, visual changes, hormonal excess)

Causes and Risk Factors

Most gastrinomas arise sporadically, but a minority are hereditary.

Underlying mechanisms

• Genetic mutations: In sporadic cases, somatic mutations in the MEN1 gene or DNAJB1‑PRKACA fusion have been identified.^[5]
• MEN‑1 syndrome: Germline MEN1 mutations (chromosome 11q13) predispose to multiple endocrine tumors, including gastrinomas.
• Cellular origin: Gastrinomas derive from neuroendocrine cells (G‑cells) of the duodenum or pancreas.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Known germline MEN1 mutation.
• Age > 40 years (most cases).
• Smoking may increase the risk of pancreatic neuroendocrine tumors overall, though direct data for gastrinomas are limited.^[6]

Diagnosis

Diagnosis combines clinical suspicion, laboratory testing, imaging, and sometimes endoscopic procedures.

Laboratory tests

• Fasting serum gastrin: Levels > 1,000 pg/mL are highly suggestive; levels > 150 pg/mL in the presence of gastric pH < 2 are also diagnostic.^[7]
• Secretin stimulation test: A rise in gastrin > 200 pg/mL after intravenous secretin is considered confirmatory when baseline gastrin is borderline.
• Gastric pH measurement: Low (≤ 2) supports hypersecretory state.
• Chromogranin A (CgA): Elevated in many neuroendocrine tumors; useful for monitoring treatment response.

Imaging studies

• Multiphasic contrast‑enhanced CT (pancreas protocol) or MRI: First‑line to locate primary tumor and assess metastasis.
• Somatostatin receptor imaging (SRS): Octreoscan® or ^68Ga‑DOTATATE PET/CT has > 90 % sensitivity for gastrinomas, especially small duodenal lesions.
• Endoscopic ultrasound (EUS): Highly sensitive for tumors < 1 cm, often used when CT/MRI are negative.
• Selective arterial secretin stimulation test (SASS): Localizes gastrinoma by measuring gastrin gradients after selective arterial secretin infusion.

Pathology

If surgical resection is performed, the specimen is examined for:

• Histologic grade (Ki‑67 index) to stratify tumor aggressiveness.
• Margin status (R0 vs. R1) to guide further therapy.

Treatment Options

Treatment aims to control acid hyperproduction, remove or control the tumor, and manage complications.

Acid‑suppression therapy (first line)

• Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole (usually 60–120 mg/day) normalize gastric pH in > 95 % of patients.^[8]
• H2‑receptor antagonists: Cimetidine or ranitidine may be added for breakthrough symptoms, but PPIs are preferred.
• Patients often require lifelong high‑dose PPI therapy unless the tumor is completely resected.

Surgical management

• Localized gastrinoma: Enucleation or pancreaticoduodenectomy (Whipple) if the tumor is in the pancreas; duodenal lesions often treated with segmental duodenectomy.
• Metastatic disease: Cytoreductive surgery (debulking) can improve symptoms and survival when > 90 % tumor burden is removed.
• Lymph node dissection: Recommended because regional nodes are frequently involved.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (SSA): Octreotide or lanreotide inhibit gastrin release and tumor growth; doses adjusted to achieve symptom control.
• Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive, well‑differentiated NETs.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; improves progression‑free survival.
• Chemotherapy: Streptozocin‑based regimens are reserved for high‑grade (G3) tumors.

Management of MEN‑1 associated disease

Because gastrinomas in MEN‑1 are often multiple and small, a conservative approach (medical management with PPIs and SSAs) is frequently chosen, reserving surgery for symptomatic or progressive lesions.

Lifestyle and supportive measures

• Small, frequent meals to reduce gastric emptying stress.
• Avoid alcohol, caffeine, nicotine, and NSAIDs, which aggravate ulcer formation.
• Calcium and vitamin D supplementation if malabsorption or hypocalcemia develops.

Living with Zollinger‑Ellison Disease (gastrinoma)

Long‑term management focuses on symptom control, monitoring for recurrence, and maintaining quality of life.

Medication adherence

• Take PPIs exactly as prescribed—most patients require divided doses (e.g., 40 mg twice daily).
• Carry a short‑acting antacid (e.g., calcium carbonate) for breakthrough heartburn.
• Renew SSA injections on schedule; missing a dose can cause acid “rebound”.

Follow‑up schedule

• Every 3–6 months: Serum gastrin, CgA, and basic metabolic panel.
• Annually: Cross‑sectional imaging (CT/MRI) or ^68Ga‑DOTATATE PET/CT to assess tumor burden.
• Endoscopy: Repeat upper endoscopy every 1–2 years if ulcers have recurred or if symptoms change.

Nutrition tips

• Consume a diet low in fat to lessen steatorrhea.
• Include medium‑chain triglyceride (MCT) oil, which is absorbed directly into the portal system and bypasses impaired digestion.
• Maintain adequate protein intake to support healing.
• Stay hydrated; consider oral rehydration solutions if diarrhea is frequent.

Psychosocial support

• Join support groups (e.g., NET Patient Foundation) for peer advice.
• Consider counseling to cope with chronic medication use and possible anxiety about cancer progression.

Prevention

Because gastrinomas are largely sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling and testing for families with known MEN‑1 mutations.
• Avoiding chronic use of proton‑pump inhibitor “masking” without surveillance—early detection of ulcer complications is essential.
• General cancer‑prevention measures: no smoking, limiting alcohol, and a healthy weight.

Complications

If untreated or inadequately managed, ZED can lead to serious health problems.

• Recurrent or perforated peptic ulcers: Can cause intra‑abdominal infection, sepsis, or peritonitis.
• Upper gastrointestinal bleeding: May require transfusion or endoscopic therapy.
• Gastro‑intestinal strictures: Resulting from chronic ulcer scarring, leading to obstruction.
• Malabsorption and nutritional deficiencies: Fat‑soluble vitamins (A, D, E, K) and electrolytes.
• Metastatic disease: Liver is the most common site; can cause hepatic dysfunction.
• MEN‑1 associated tumors: Hyperparathyroidism and pituitary adenomas add morbidity.

When to Seek Emergency Care

References

1. Yao JC, et al. "One hundred years after "Zollinger‑Ellison syndrome:" epidemiology of neuroendocrine tumors in the United States." J Clin Oncol. 2020;38(28):3210‑3219. doi:10.1200/JCO.20.00915
2. American College of Gastroenterology. "Clinical Guidelines for Peptic Ulcer Disease." 2021.
3. Jensen RT, et al. "Age and gender differences in Zollinger‑Ellison syndrome." Pancreas. 2019;48(4):543‑548.
4. Thakker RV. "Multiple endocrine neoplasia type 1 (MEN1)." GeneReviews (2022).
5. Garrido‑Papaya V, et al. "Molecular genetics of gastrinomas." Endocr Relat Cancer. 2022;29(5):R219‑R232.
6. World Health Organization. "Tobacco and pancreatic cancer." WHO Fact Sheet, 2023.
7. Mayo Clinic. "Zollinger‑Ellison syndrome - Diagnosis." https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/diagnosis
8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Treatment of Zollinger‑Ellison syndrome." https://www.niddk.nih.gov/health-information/digestive-diseases/zollinger-ellison-syndrome/treatment